Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Michael L. Ganz, Neil S. Wintfeld, Qian Li, Yuan-Chi Lee, Elyse Gatt & Joanna C. Huang. (2014) Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States. Current Medical Research and Opinion 30:10, pages 1991-2000.
Read now
Read now
Urpo Kiiskinen, Stephan Matthaei, Matthew Reaney, Chantal Mathieu, Claes-Göran Östenson, Thure Krarup, Michael Theodorakis, Jacek Kiljański, Carole Salaun-Martin, Hélène Sapin & Bruno Guerci. (2013) Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study. ClinicoEconomics and Outcomes Research 5, pages 355-367.
Read now
Read now
Elise M. Pelletier, Manjiri Pawaskar, Paula J. Smith, Jennie H. Best & Richard H. Chapman. (2012) Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis. Journal of Medical Economics 15:6, pages 1039-1050.
Read now
Read now
Manjiri Pawaskar, Qian Li & Matthew W. Reynolds. (2012) Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting. Current Medical Research and Opinion 28:6, pages 991-997.
Read now
Read now
Devesh Sennik, Fahad Ahmed & David Russell-Jones. (2012) Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 7:1, pages 15-26.
Read now
Read now
Articles from other publishers (8)
Meir Schechter, Matan Fischer & Ofri Mosenzon. (2022)
Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and
glucagon‐like peptide
‐1 receptor agonists: A narrative review and proposed clinical approach
. Diabetes, Obesity and Metabolism 24:6, pages 969-982.
Crossref
Crossref
Sarah M Khayyat, Philippa A Walters, Cate Whittlesea & Hamde Nazar. (2022) Interventions developed to reduce secondary care utilisation in patients with type 2 diabetes mellitus: a narrative review. International Journal of Pharmacy Practice 30:2, pages 116-128.
Crossref
Crossref
Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang & Hengjin Dong. (2017) Cost‐effectiveness of exenatide twice daily vs insulin glargine as add‐on therapy to oral antidiabetic agents in patients with type 2 diabetes in China. Diabetes, Obesity and Metabolism 19:12, pages 1688-1697.
Crossref
Crossref
A.S. Geier, I. Wellmann, J. Wellmann, H. Kajüter, O. Heidinger, G. Hempel & H.W. Hense. (2014) Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 106:1, pages 73-80.
Crossref
Crossref
P Karagianni, SA Polyzos, N Kartali, I Zografou & C Sambanis. (2013) Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy. Advances in Medical Sciences 58:1, pages 38-43.
Crossref
Crossref
Douglas Faries, Xiaomei Peng, Manjiri Pawaskar, Karen Price, James D. Stamey & John W. SeamanJr.Jr.. (2013) Evaluating the Impact of Unmeasured Confounding with Internal Validation Data: An Example Cost Evaluation in Type 2 Diabetes. Value in Health 16:2, pages 259-266.
Crossref
Crossref
M. Pawaskar, Q. Li, B. J. Hoogwerf, M. W. Reynolds, D. Faries, W. Engelman, D. Bruhn & R. M. Bergenstal. (2012) Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting. Diabetes, Obesity and Metabolism 14:7, pages 626-633.
Crossref
Crossref
J. H. Best, K. Lavillotti, M. B. DeYoung & L. P. Garrison. (2011) The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review. Diabetes, Obesity and Metabolism 14:5, pages 387-398.
Crossref
Crossref